Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.658519/full |
id |
doaj-56b0779b74c843e8bf46c65291cac1a2 |
---|---|
record_format |
Article |
spelling |
doaj-56b0779b74c843e8bf46c65291cac1a22021-06-30T07:00:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-06-011210.3389/fimmu.2021.658519658519Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent UpdateUttpal Anand0Shweta Jakhmola1Omkar Indari2Hem Chandra Jha3Zhe-Sheng Chen4Vijay Tripathi5José M. Pérez de la Lastra6Department of Life Sciences, National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, IsraelDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, IndiaDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, IndiaDiscipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore, Indore, IndiaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, United StatesDepartment of Molecular and Cellular Engineering, Jacob Institute of Biotechnology and Bioengineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, IndiaInstituto de Productos Naturales y Agrobiología (IPNA), Consejo Superior de Investigaciones científicas (CSIS), Santa Cruz de Tenerife, SpainSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.https://www.frontiersin.org/articles/10.3389/fimmu.2021.658519/fullCOVID-19vaccinetherapeutic targetspeptideantibodiestreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Uttpal Anand Shweta Jakhmola Omkar Indari Hem Chandra Jha Zhe-Sheng Chen Vijay Tripathi José M. Pérez de la Lastra |
spellingShingle |
Uttpal Anand Shweta Jakhmola Omkar Indari Hem Chandra Jha Zhe-Sheng Chen Vijay Tripathi José M. Pérez de la Lastra Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update Frontiers in Immunology COVID-19 vaccine therapeutic targets peptide antibodies treatment |
author_facet |
Uttpal Anand Shweta Jakhmola Omkar Indari Hem Chandra Jha Zhe-Sheng Chen Vijay Tripathi José M. Pérez de la Lastra |
author_sort |
Uttpal Anand |
title |
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update |
title_short |
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update |
title_full |
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update |
title_fullStr |
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update |
title_full_unstemmed |
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update |
title_sort |
potential therapeutic targets and vaccine development for sars-cov-2/covid-19 pandemic management: a review on the recent update |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2021-06-01 |
description |
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19. |
topic |
COVID-19 vaccine therapeutic targets peptide antibodies treatment |
url |
https://www.frontiersin.org/articles/10.3389/fimmu.2021.658519/full |
work_keys_str_mv |
AT uttpalanand potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate AT shwetajakhmola potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate AT omkarindari potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate AT hemchandrajha potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate AT zheshengchen potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate AT vijaytripathi potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate AT josemperezdelalastra potentialtherapeutictargetsandvaccinedevelopmentforsarscov2covid19pandemicmanagementareviewontherecentupdate |
_version_ |
1721353126358810624 |